Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer

ANZ Journal of Surgery

Volumn 81, Issue 10, 2011, Pages 694-699

  Wang, Tian Bao ^a   Chen, Zhong Gang ^a   Wei, Xiu Qing ^a   Wei, Bo ^a   Dong, Wen Guang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Lymph node metastasis; Lymphoangiogenesis; Serum VEGF C; Survival

Indexed keywords

MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN C;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CANCER STAGING; CHINA; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 80053460345     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2010.05539.x     Document Type: Article

References (40)

1. Wang TB, Qiu WS, Wei B, Deng MH, Dong WG. Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors. Ir. J. Med. Sci. 2009; 178: 315-20.
2. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J. Gastroenterol. 2002; 8: 994-8.
3. Joukov V, Pajusola K, Kaipainen A etal. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15: 290-8.
4. Enholm B, Jussila L, Karkkainen M, Alitalo K. Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells. Trends Cardiovasc. Med. 1998; 8: 292-7.
5. Mimura T, Amano S, Usui T, Kaji Y, Oshika T, Ishii Y. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp. Eye Res. 2001; 72: 71-8.
6. Ueda M, Terai Y, Kumagai K etal. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol. Oncol. 2001; 82: 162-6.
7. Yonemura Y, Fushida S, Bando E etal. Lymphangiogenesis and the vascular endothelial growth factor receptor(VEGFR)-3 in gastric cancer. Eur. J. Cancer 2001; 37: 918-23.
8. Amioka T, Kitadai Y, Tanaka S etal. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer 2002; 38: 1413-9.
9. Liu XE, Sun XD, Wu JM. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J. Gastroenterol. 2004; 10: 352-5.
10. Yan C, Zhu ZG, Yu YY etal. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J. Gastroenterol. 2004; 10: 783-90.
11. Kitadai Y, Kodama M, Cho S etal. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int. J. Cancer 2005; 115: 388-92.
12. Kishimoto K, Sasaki A, Yoshihama Y, Mese H, Tsukamoto G, Matsumura T. Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol. 2003; 39: 391-6.
13. Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S, Muller W. VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol. Rep. 2002; 9: 995-9.
14. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003; 97: 457-64.
15. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003; 98: 1217-22.
16. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J. Gastroenterol. 2007; 13: 1794-8.
17. Mathur SP, Mathur RS, Gray EA etal. Serum vascular endothelial growth factor-C(VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol. Oncol. 2005; 98: 467-83.
18. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, Sekiya S. Serum vascular endothelial growth factor(VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005; 103: 724-30.
19. Tamura M, Oda M, Matsumoto I etal. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9 and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann. Surg. Oncol. 2004; 11: 928-33.
20. Tamura M, Oda M, Tsunezuka Y etal. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 2004; 126: 342-6.
21. Miyazaki T, Okada N, Ishibashi K etal. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer. Jpn. J. Clin. Oncol. 2008; 38: 839-43. Epub 2008 Oct 15.
22. Xu T, Chen D. Serum vascular endothelial growth factor-C and vascular endothelial growth factor level in patients with colorectal carcinoma and clinical significance. J. Huazhong Univ. Sci. Technol. Med. Sci. 2006; 26: 329-31, 355.
23. Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J. Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int. J. Colorectal Dis. 2009; 24: 269-74.
24. Yonemura Y, Endo Y, Fujita H etal. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 1999; 5: 1823-9.
25. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor(VEGF) and VEGF-C in gastric carcinoma. J. Surg. Oncol. 2001; 78: 132-7.
26. Takahashi A, Kono K, Itakura J etal. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002; 62: 121-7.
27. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Banas T. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett. 2007; 249: 171-7.
28. Bogos K, Renyi-Vamos F, Dobos J etal. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res. 2009; 15: 1741-6.
29. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M etal. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J. Gastroenterol. 2008; 14: 3879-83.
30. Kimura H, Kato H, Tanaka N etal. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res. 2008; 28: 165-9.
31. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta. Oncol. 2007; 46: 678-84.
32. Yu XM, Lo CY, Lam AK, Leung P, Luk JM. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 2008; 247: 483-9.
33. Li EX, Shi F, Wu YY, Wu Y, Guo JJ, Dong DF. The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer. Zhonghua Yi Xue Za Zhi 2008; 88: 88-91.
34. Skobe M, Hawighorst T, Jackson DG etal. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001; 7: 192-8.
35. Munoz-Guerra MF, Marazuela EG, Martin-Villar E, Quintanilla M, Gamallo C. Prognostic significance of intratumoral lymphangiogenesis in squamous cell carcinoma of the oral cavity. Cancer 2004; 100: 553-60.
36. Massi D, Puig S, Franchi A etal. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J. Clin. Pathol. 2006; 59: 166-73.
37. Brundler MA, Harrison JA, de Saussure B, de Perrot M, Pepper MS. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma. J. Clin. Pathol. 2006; 59: 191-5.
38. Roma AA, Magi-Galluzzi C, Kral MA, Jin TT, Klein EA, Zhou M. Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma. Mod. Pathol. 2006; 19: 392-8.
39. Lin J, Lalani AS, Harding TC etal. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005; 65: 6901-9.
40. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007; 98: 726-33.